Therapeutic use of anti-CS1 antibodies
AssigneeAbbott Biotherapeutics Corp.
InventorsMarna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
Claims16
A monoclonal antibody or antigen binding fragment that binds a protein encoded by SEQ ID NO:1 and inhibits immunoglobulin secretion, wherein said antibody or antigen binding fragment decreases by at least 50% in a competitive binding assay the binding to a protein encoded by SEQ ID NO:1 of a control antibody obtainable from a hybridoma bearing ATCC designation No. PTA-5091.
Dependencies are inferred from the claim text.